期刊文献+

骶骨脊索瘤CD40、PCNA、CD31表达及其与肿瘤复发的相关性研究 被引量:2

Expressions of CD40,PCNA,CD31 in human chordoma and their relationship with recurrence of chordoma
原文传递
导出
摘要 [目的]研究骶骨脊索瘤中CD40、PCNA、CD31的表达水平及其与脊索瘤复发的相关性。[方法]采用EnVi-sionTM免疫组化技术检测28例骶骨脊索瘤组织、9例正常胚胎脊索组织中的CD40和PCNA的表达,并计数CD31标记的肿瘤组织微血管密度(MVD)。[结果]①CD40、PCNA在骶骨脊索瘤中的强阳性表达率分别为66.1%、64.3%,明显高于正常胚胎脊索组织。两者之间的差异有统计学意义(P<0.05);骶骨脊索瘤中CD31标记的微血管密度(24.26±18.68)/mm2,正常胚胎脊索组织微血管密度值为(4.63±2.19)/mm2;差异有统计学意义(P<0.05);②28例骶骨脊索瘤,其中复发组14例,非复发组14例,两组间CD40阳性表达率分别为14.29%、85.71%;PCNA阳性表达率分别为92.86%、50.00%;CD31标记的MVD值分别为(30.66±23.75)/mm2、(17.88±8.52)/mm2;均有统计学差异(P<0.05);③CD40、PCNA表达及CD31标记的MVD值与患者的年龄、性别、肿瘤大小无统计学相关性;④PCNA阳性表达的骶骨脊索瘤组织中MVD值为(28.92±20.27)/mm2,明显高于PCNA阴性组(12.64±3.70)/mm2,差异有统计学意义(P<0.05)。CD40阴性表达的骶骨脊索瘤组织中MVD值为(31.68±22.81)/mm2,明显高于CD40阳性表达组(16.86±9.28)/mm2,差异有统计学意义(P<0.05)。[结论]骶骨脊索瘤中CD40、PCNA、CD31表达水平可作为判断病情进展和肿瘤复发的指标。 [Objective]To study the expressions of CD40,PCNA and CD31 in human chordoma tissues and the relationship with the recurrence of chordoma. [Methods]CD40,PCNA and CD31 were detected by EnVisionTM immunohistochemistry method in 28 human chordoma tissues and 9 normal notochord tissues.The tumor microvascular density(MVD) marked by CD31 were counted.[Results]①The positive expression rates of CD40 and PCNA in chordoma were 66.1% and 64.3%.They were significantly higher than those in the normal notochord tissues(P0.05).The MVD marked by CD31 was 24.26±18.68/mm2 in the chordoma tissues and was 4.63±2.19/mm2 in the normal notochord tissue.There was significant difference(P0.05).②Of the 28 chordoma patients,14 were diagnosed with recurrence.The positive expressions of CD40 in the recurrence group and non-recurrence group were 14.29% and 85.71% and 92.86% and 50.00% for the PCNA.The CD31 marked MVD was 30.66±23.75/mm2 in the recurrence group and 17.88±8.52/mm2 in the non-recurrence group.There was significantly difference between the two groups(P0.05).③There was no statistical relationship between the expression of CD40,PCNA,MVD versus age,gender,and tumor size.④ The MVD in the positive expression group of PCNA was 28.92±20.27/mm2.It was significantly higher than that in the negative expression group(12.64±3.70 /mm2)(P0.05).The MVD in the negative expression group of CD40 was 31.68±22.81/mm2.It was significantly higher than that in the positive expression group(16.86±9.28/mm2)(P0.05).[Conclusion]The expression of CD40,PCNA and CD31 in chordoma could be used to estimate the progression and recurrence.
出处 《中国矫形外科杂志》 CAS CSCD 北大核心 2011年第14期1197-1200,共4页 Orthopedic Journal of China
关键词 骶骨 脊索瘤 CD31 CD40 PCNA 复发 sacral bone chordoma CD31 CD40 PCNA recurrence
  • 相关文献

参考文献10

二级参考文献55

  • 1李守强,徐微尘,李妹,崔东艳.术前动脉栓塞在骶骨肿瘤治疗中的价值[J].中国矫形外科杂志,2004,12(13):977-979. 被引量:15
  • 2米川,马忠泰,卢海霖,徐阳.球囊导管阻断动脉控制肿瘤术中出血的可行性研究[J].中华骨科杂志,2005,25(5):280-283. 被引量:33
  • 3李盛美,毕五蝉,孟淑琴,张清,徐万鹏.骶骨脊索瘤的临床病理分析[J].中华骨科杂志,1994,14(11):653-655. 被引量:10
  • 4Joshi BH, Plautz GE, Puff RK. Interleukin-13 receptor alpha chain: a novel tumor-associated transmembrane protein in primary explants of human malignant gliomas [J]. Cancer Res, 2000, 60 (5) : 1168-1172.
  • 5Debinski W, Gibo DM, Hulet SW, et al. Receptor for interleukin 13 is a marker and therapeutic target for human malignant gliomas [J]. Clin Cancer Res, 1999, 5(5) : 985-990.
  • 6Donaldson DD, Whitters MJ, Fitz LJ, et al. The murine IL-13 receptor alpha 2 : molecular cloning, characterization, and compari- son with murine IL-13 receptor alpha 1 [ J]. J Immunol, 1998, 161 (5) : 2317-2324.
  • 7Oshima Y, Joshi BH, Puri RK. Conversion of interleukin-13 into a high affinity agonist by a single amino aeid substitution[J]. J Biol Chem, 2000, 275 (19): 14375-14380.
  • 8Kawakami M, Kawakami K, Kasperbauer JL, et al. Interleukin- 13 receptor alpha 2 chain in human head and neck cancer serves as a unique diagnostic marker [J]. Clin Cancer Res, 2003, 9 (17) : 638145388.
  • 9Kawakami K, Taguchi J, Murata T, et al. The interleukin-13 receptor alpha 2 chain: an essential component for binding and in- ternalization but not for interleukin-13-induced signal transduction through the STAT6 pathway [J]. Blood, 2001, 97(9): 2673- 2679.
  • 10Rahaman SO, Shanna P, Harbor PC, et al. IL-13R(alpha)2, a decoy receptor for IL-13 acts as an inhibitor of IL-4-dependent signal transdnction in glioblastoma cells [J]. Cancer Res, 2002, 62 (4) : 1103-1109.

共引文献29

同被引文献30

  • 1孙建军,经巍,倪艳艳,袁小建,周海华,范跃祖.一种新的人结肠腺癌淋巴管生成裸鼠动物模型[J].外科研究与新技术,2012,1(1):49-55. 被引量:2
  • 2牟江洪,阎晓初,李增鹏,王东,段光杰,向德兵,肖华亮,张沁宏.结直肠癌淋巴管生成的特点及其临床病理意义[J].中华病理学杂志,2005,34(6):348-352. 被引量:39
  • 3张江宇,王颀,张雅洁.CD105与肿瘤关系的研究进展[J].中华肿瘤防治杂志,2007,14(18):1433-1436. 被引量:4
  • 4Sumpio BE, Yun S, Cordova AC, et al. MAP Kinase (ERK1/2, p38) and AKT can he phosphorylated by shear stress independently of PECAM-1 (CD31) in vascular endothelial cells. J Biol Chem, 2005, 280 (12): 11185-11191.
  • 5Ding S, Li C, Lin S, et al. Comparative evaluation of microvessel density determined by CD34 or CD105 in benign and malignant gastric lesions. Hum Pathol, 2006,37 (7): 861-867.
  • 6Dhanuthai K, Sappayatosok K, Yodsanga S, et al. An analysis of microvessel density in salivary gland tumours: A single centre study. The Surgeon(in press), 2012.
  • 7Weidner N, Folkman J, Pozza F, et al. Tumor angiogenesis: a new significant and independent prognosis in dicator in early-stage breast carcinoma. J Natl Cancer Inst,1992,84(24):1875-1887.
  • 8Kiss J, Timar J, Somlai B, et al. Association of microvessl density with infiltrating cells inhuman cutaneous malignant melanoma. Pathol Oncol Res, 2007, 13 (1):21-31.
  • 9Hasan J, Byers R, Jayson GC. Intratumoural microvessel density in human solid tumours. Br J Cancer, 2002,86 (10) : 1566-1577.
  • 10Soares AB, Juliano PB, Arau'jo VC, et al. Angiogenic switch during tumour progression of carcinoma ex-pleomorphic adenoma. Virchows Arch,2007,451..65-71.

引证文献2

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部